Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC44H48FN9O7 |
InChIKeyPNTOZYCYTGDKDX-UHFFFAOYSA-N |
CAS Registry2472644-70-3 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Neoplasms | Preclinical | United States | 28 Oct 2019 |





